#GlobalCMTResearchConvention
Join us for CMT’s largest and most engaging global convention, bringing together the scientific community and patients in a single event.
The CMT Research Foundation is laser-focused on delivering treatments and cures for Charcot-Marie-Tooth disease during our lifetime.
The 2022 Global CMT Research Convention will gather researchers, pharmaceutical companies, biotech companies, government and patients to discuss and find solutions for the most pressing problems in CMT research.
Come learn what the future holds for CMT research and how you can help end this disease!
For the Scientific Community
September 16th
A day for researchers, industry and government agencies to:
SHARE the latest in CMT drug development research
CREATE new connections and collaborations
EXAMINE the most pressing issues facing CMT drug development
Featured speaker: Chris Austin, Flagship Pioneering
Agenda
Click here to see the full day of event agenda
TBD by April 15th
Keynote Speaker
Robert "Bob" Baloh, MD, PhD
Roche
Switzerland
Zarife Sahenk, MD, PhD
Nationwide Children’s Hospital
United States
Kleopas Kleopa, MD
Cyprus Institute of Neurology & Genetics
Cyprus
For the Patient Community
September 17th
A day for the patient community to:
LEARN about the latest CMT research developments and clinical trials
INTERACT with distinguished scientific experts
ACT to speed treatments for patients and families
A salute to the achievements and pioneers that have paved the way towards a cure and preview the work to come that will end CMT once and for all.
Agenda
Click here to see the full day of event agenda
TBD by April 15th
Keynote Speaker
Amanda Haidet-Phillips, PhD
Novartis Gene Therapies
United States
David Herrmann, MBBCh
United States
William Motley, MD, DPhil
Flare Therapeutics
United States
Thank You to Our Sponsors!
The Scientific Programming Committee
Marina Kennerson, PhD
Co-Chair
Professor of Neurogenetics and Neuroscience
ANZAC Research Institute and University of Sydney, Australia
Charles Abrams, MD, PhD
Co-Chair
Professor of Neurology and Rehabilitation
University of Illinois, Chicago (UIC)
Edritz Javelosa, PhD
Research Portfolio Director
Muscular Dystrophy Association
Paul August, PhD
Vice President, Biology Department Head & Preclinical GDD Portfolio Leader
Agios Pharmaceuticals
Amanda Haidet-Phillips, PhD
Senior Director, Translational Medicine
Novartis Institutes for BioMedical Research
Dennis Klein, PhD
Research Scientist, Department of Neurology
University Hospital Wuerzburg, Germany
Glen Nuckolls, PhD
Program Director, Neurogenetics, Division of Neuroscience
U.S. National Institute of Neurological Disorders and Stroke (NINDS)
Tiina Urv, PhD
Program Director, Office of Rare Diseases Research
U.S. National Center for Advancing Translational Sciences (NCATS)
Alessandra Bolino, PhD
Group Leader, Human Inherited Neuropathies Unit
San Raffaele Scientific Institute, Milan, Italy